DDInter93 DDInter1747
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
Anagrelide {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 3 Inhibitors
Anagrelide {u} (Compound) downregulates {v} (Gene) TM9SF2
Anagrelide {u} (Compound) causes {v} (Side Effect) Distress gastrointestinal
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milrinone
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Vorapaxar
Anagrelide (Compound) treats hematologic cancer (Disease)
Anagrelide (Compound) binds CYP1A2 (Gene)
Anagrelide (Compound) upregulates HMG20B (Gene)
Anagrelide (Compound) is included by Phosphodiesterase 3 Inhibitors (Pharmacologic Class)
Anagrelide (Compound) downregulates TM9SF2 (Gene)
Anagrelide (Compound) causes Distress gastrointestinal (Side Effect)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milrinone
Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar